In October 2022, during a routine follow-up visit, serum carcinoembryonic antigen (CEA) levels had risen to 27.44 ng/mL (normal range: 0–6 ng/mL), prompting an abdominal ultrasound that revealed prostate enlargement. This evidence concerns the gene CEACAM5 and benign prostatic hyperplasia.